2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paoletti, E. Articles by Cannella, G. Search for Related Content PubMed PubMed Citation Articles by Paoletti, E. Articles by Cannella, G.

Update on Erythropoietin Treatment: Should Hemoglobin Be Normalized in Patients with Chronic Kidney Disease?

Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria San Martino, Genova, Italy

Address correspondence to: Dr. Ernesto Paoletti, Divisione di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria San Martino, Genova, Italy. Phone: +39-010-555-3878; Fax: +39-010-555-6652; E-mail: ernesto.paoletti{at}hsanmartino.it

The partial correction of ESRD anemia by recombinant human erythropoietin (EPO) has resulted both in generalized improvement in quality of life and physical activity and in reduced mortality and hospitalization rate. The question remains as to whether normalizing hemoglobin (Hgb) is desirable in patients with chronic kidney disease (CKD). This review provides an analysis and commentary on the available reports and, for the most part, randomized, controlled trials on the topic. In dialysis patients, normalization of Hgb is associated with improved quality of life and exercise capacity but not with reduced mortality and hospitalization rate. Moreover, no significant changes in the degree of left ventricular hypertrophy have been demonstrated. By contrast, an increased mortality rate has been reported for hemodialysis patients with overt cardiovascular disease (CVD) when randomly assigned to normal hematocrit by EPO. Data regarding patients who have CKD but are not yet on renal replacement therapy are scarce, and the effects of EPO on renal disease progression require further elucidation through controlled trials. The conclusion that can be drawn from the available studies is that Hgb >11 g/dl is the minimum required to achieve improved quality of life in patients with CKD, whereas values >12 g/dl are not recommended for patients with overt CVD. Finally, Hgb normalization might reasonably be restricted to a selected population of younger, employed, and active individuals, provided that they do not have CVD.

This article has been cited by other articles:

				C. Chazot, J. C. Terrat, A. Dumoulin, K.-S. Ang, J. P. Gassia, K. Chedid, F. Maurice, B. Canaud, and the Conference Medical Group Randomized Equivalence Study Evaluating the Possibility of Switching Hemodialysis Patients Receiving Subcutaneous Human Erythropoietin Directly to Intravenous Darbepoetin Alfa Ann. Pharmacother., February 1, 2009; 43(2): 228 - 234. [Abstract] [Full Text] [PDF]

				A. O. Staples, C. S. Wong, J. M. Smith, D. S. Gipson, G. Filler, B. A. Warady, K. Martz, and L. A. Greenbaum Anemia and Risk of Hospitalization in Pediatric Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 48 - 56. [Abstract] [Full Text] [PDF]

				K. L. Cavanaugh Diabetes Management Issues for Patients With Chronic Kidney Disease Clin. Diabetes, July 1, 2007; 25(3): 90 - 97. [Abstract] [Full Text] [PDF]

				L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin Hypertension, May 1, 2007; 49(5): 1142 - 1148. [Abstract] [Full Text] [PDF]

				D. W. Coyne Influence of Industry on Renal Guideline Development Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 3 - 7. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673